Non-CME Courses

Title Banner Date Description
Reducing Disease Risk and Extending Life: Rethinking the Role of Menopausal Hormone Therapy (Online)
Tuesday, May 15, 2018 7:30 AM - Friday, August 31, 2018 1:01 PM The Anlyan Center (TAC), New Haven, CT

Specialties: Cardiovascular Disease, Family Practice, General Practice, Gynecology, Internal Medicine, Obstetrics, Psychiatry

This Symposium aims to increase knowledge about the risks of untreated estrogen deficiency and about the efficacy and safety of ET. We hope this increase in knowledge will lead more healthcare professionals to recognize and evaluate their women patients for estrogen deficiency and to consider prescribing ET or referring to a specialist who is trained and experienced in menopause healthcare.

Impact on Healthcare Professionals Knowledge and Patient Care
Although extensive information is available supporting the role of estrogens for primary care prevention of cardiovascular and other diseases in women after hysterectomy, this information is not widely known or appreciated by either healthcare professionals or women themselves. The first report of the Women’s Health Initiative (WHI) estrogen plus progestogen findings in 2002 led to fear of all menopause hormone therapies. The 2004 WHI estrogen only (ET) findings in women who had a hysterectomy reported major benefits and minimal adverse effects of ET, but went largely unnoticed. Despite these positive findings, use of ET after hysterectomy steeply declined from more than 90% to less than 10%. Not using ET has left millions of women with menopause symptoms untreated and at increased disease risk. More than 50,000 deaths largely due to cardiovascular disease, have been attributed to non-use of ET after hysterectomy.